Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Moiola

Showing results (51-60 of 154) with videos related to

Pageof 16
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2016
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapiesDamiano Baroncini, Angelo Ghezzi, Pietro O Annovazzi, et al.
European Journal of Neurology|June 30, 2025
Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple SclerosisFerdinando Clarelli, Melissa Sorosina, Antonino Giordano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 21, 2025
Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosisMarco Pisa, Tommaso Croese, Gloria Dalla Costa, et al.
Viruses|May 11, 2016
Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with NatalizumabRoberta Antonia Diotti, Ruggero Capra, Lucia Moiola, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2019
Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple SclerosisPaolo Preziosa, Maria A Rocca, Gianna C Riccitelli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 12, 2015
Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosisSara Cirillo, Maria A Rocca, Angelo Ghezzi, et al.
Journal of Neurology|June 27, 2022
Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patientsMiryam Cannizzaro, Laura Ferré, Ferdinando Clarelli, et al.
Journal of Neuroimmunology|December 1, 2015
Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromesGloria Dalla Costa, Gabriella Passerini, Maria Josè Messina, et al.
Current Rheumatology Reports|July 1, 2021
Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and AlexithymiaLuca Moroni, Martina Mazzetti, Giuseppe Alvise Ramirez, et al.
Annals of Neurology|February 18, 2021
Early Predictors of 9-Year Disability in Pediatric Multiple SclerosisErmelinda De Meo, Raffaello Bonacchi, Lucia Moiola, et al.
Pageof 16

Showing results (51-60 of 154) with videos related to

Sort By:
Pageof 16
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2016
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapiesDamiano Baroncini, Angelo Ghezzi, Pietro O Annovazzi, et al.
European Journal of Neurology|June 30, 2025
Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple SclerosisFerdinando Clarelli, Melissa Sorosina, Antonino Giordano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 21, 2025
Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosisMarco Pisa, Tommaso Croese, Gloria Dalla Costa, et al.
Viruses|May 11, 2016
Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with NatalizumabRoberta Antonia Diotti, Ruggero Capra, Lucia Moiola, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2019
Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple SclerosisPaolo Preziosa, Maria A Rocca, Gianna C Riccitelli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 12, 2015
Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosisSara Cirillo, Maria A Rocca, Angelo Ghezzi, et al.
Journal of Neurology|June 27, 2022
Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patientsMiryam Cannizzaro, Laura Ferré, Ferdinando Clarelli, et al.
Journal of Neuroimmunology|December 1, 2015
Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromesGloria Dalla Costa, Gabriella Passerini, Maria Josè Messina, et al.
Current Rheumatology Reports|July 1, 2021
Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and AlexithymiaLuca Moroni, Martina Mazzetti, Giuseppe Alvise Ramirez, et al.
Annals of Neurology|February 18, 2021
Early Predictors of 9-Year Disability in Pediatric Multiple SclerosisErmelinda De Meo, Raffaello Bonacchi, Lucia Moiola, et al.
Pageof 16